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In this retrospective cohort study, selected patients with dis-
seminated Staphylococcus aureus bacteremia, but without 
endovascular infection on echocardiography and 18F-FDG-
PET/CT, were free of relapse after IV-oral switch. Mortality was 
low and similar to patients who received prolonged intravenous 
treatment. IV-oral switch was associated with a shorter length 
of hospital stay.
Keywords.  Staphylococcus aureus; bacteremia; treatment; 
IV-oral switch.  
In complicated Staphylococcus aureus bacteremia (SAB), guide-
lines recommend prolonged intravenous (IV) antibiotic therapy 
for at least 4–6 weeks [1]. Few studies suggest the safety of se-
quential IV to oral switch in these patients [2, 3]. Also, bone 
and joint infections, which are common metastatic infections 
in SAB, can be safely managed with predominant oral treatment 
[4]. In these patients, early IV-oral switch is associated with 
shorter hospital stay and fewer complications [4]. Our institute 
has the policy that patients with SAB with nonendovascular 
metastatic infectious foci can be treated with oral antibiotics 
after 14  days of IV treatment. This study determined the 
outcome and adverse events of this strategy in comparison to 
prolonged IV treatment.
METHODS
In this retrospective observational study, all adult patients with 
complicated SAB, defined as the presence of metastatic infec-
tions, admitted to our hospital from 2013 until 2020 were el-
igible for inclusion. Exclusion criteria were endocarditis or 
other endovascular infections, no 2-[18F]fluoro-2-deoxy-D-
glucose–positron emission tomography/computed tomography 
(18F-FDG-PET/CT) and echocardiography performance, and 
death within 14 days. The regional ethics committee approved 
this study and waived the requirement to obtain informed con-
sent (no. 2019–6025). We manually retrieved clinical character-
istics of all patients (Table 1) from the electronic medical charts, 
including outcome 3 months after discontinuation of treatment.
All patients with SAB underwent both echocardiography and 
18F-FDG-PET/CT to search for endocarditis or metastatic in-
fection as described elsewhere [5]. Additionally, bedside con-
sultation by an infectious disease specialist was mandatory and 
source control including surgical drainage was performed, if 
possible. Flucloxacillin was the preferred initial IV treatment, 
with cefazolin as an alternative in case of allergy or adverse 
events. In patients with complicated SAB but without evidence 
of endovascular infection on echocardiography and 18F-FDG-
PET/CT, the institutional guideline recommended IV-oral 
switch after 2 weeks of IV treatment. The preferred oral regimen 
was clindamycin 600  mg 3 times/day fixed dose. Antibiotic 
treatment duration in SAB with metastatic foci was based on 
the following institutional guidelines: SAB and arthritis as met-
astatic infection, 4 weeks; vertebral osteomyelitis (without ep-
idural abscesses), 6 weeks; soft tissue or visceral abscesses, 6 
weeks; and for pulmonary foci, 6 weeks. Duration of antibiotic 
treatment could be prolonged based on clinical status. Patients 
with IV-oral switch were compared with patients without 
IV-oral switch.
The primary outcome parameter was relapse of infection—
that is, a new episode of SAB within 3 months after discontin-
uation of antibiotic treatment. Secondary outcome parameters 
were 3-month all-cause mortality, length of hospital stay, and 
adverse events (Table 1). The presence of liver toxicity or acute 
kidney injury (AKI) was defined as the decision of the attending 
physician to switch antibiotic treatment because of elevated 
liver enzyme concentrations or creatinine concentrations.
SPSS (version 22.0; SPSS, Inc) was used for analyzing data. 
Unpaired Student’s t tests were used to compare normally dis-
tributed, continuous variables; otherwise, the Mann-Whitney 
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of the chi-square test or Fisher’s exact test. Differences were 
considered statistically significant at a 2-sided P value of less 
than .05. With these analyses, the sample size of 106 had lim-
ited power to detect differences in relapse rate: 30% power 
to detect a 2-fold increase from 10% to 20% or 38% power 
to detect a 3-fold increase from 5% to 15%. The sample size 
provided adequate power to detect moderate effect sizes in 
continuous secondary parameters: 72% power to detect a 
standardized effect size of 0.5. Hence, analyses are primarily 
descriptive.
RESULTS
A total of 106 patients were included: 45 patients (42.5%) re-
ceived only IV antibiotics and 61 patients (57.5%) underwent 
IV-oral switch. Baseline characteristics are shown in Table 1. 
Patients with prolonged IV antibiotic treatment more often had 
persistent fever and persistently positive blood cultures.
Median treatment duration in the prolonged IV treatment group 
was 45 days (interquartile range [IQR], 44; range, 12–356 days) 
and in the IV-oral switch group was 45  days (IQR, 49; range, 
17–149  days) (P = .355). IV-oral switch took place after a me-
dian of 16 days (IQR, 4; range, 12–19 days) and oral clindamycin 
was prescribed to 88.5% of patients. Of all patients, 95 (89.6%) 
received flucloxacillin as first IV antibiotic treatment, of whom 
18 patients (17.0%) were switched to cefazolin due to AKI (8; 
44.4%), nausea (3; 16.7%), rash (2; 11.1%), phlebitis (1; 5.5%), or 
other reasons (4; 22.2%). IV-IV antibiotic switch of flucloxacillin 
to cefazolin occurred more often in the prolonged IV treatment 
group (28.9% vs 8.2%, respectively; P = .011). Three-month fol-
low-up was available in all but 1 surviving patient (99.1%). No re-
lapses were observed (Table 1). Three-month mortality was 13.3% 
in the prolonged IV group versus 6.6% in the IV-oral switch group 
(P = .242). Median hospital admission duration was 29 days (IQR, 
33; range, 9–129  days) in the prolonged IV group and 17  days 
(IQR, 11; range, 9–67 days) in the IV-oral switch group (P = .001).
Table 1.  Baseline Characteristics and Outcome in All Patients With Staphylococcus aureus Bacteremia
Prolonged IV Antibiotic Treatment (n = 45) IV-Oral Switch (n = 61) P
Male, n (%) 27 (60.0) 44 (72.1) .193
Mean age, years 61.4 58.9 .926
Charlson comorbidity index 3.8 3.3 .446
Community acquisition, n (%) 19 (42.2) 28 (45.9) .883
Persistent fever (>72 hours), n (%) 27 (60.0) 24 (39.3) .043
Persistent positive blood cultures (>48 hours), n (%) 25 (55.6) 14 (22.9) .001
Signs of infection >48 hours before start of adequate therapy, n (%) 20 (44.4) 26 (42.6) .832
MRSA, n (%) 2 (4.4) 2 (3.3) 1.000
Metastatic infection, n (%)    
 Vertebral osteomyelitis 14 (31.1) 9 (14.8) .044
 Nonvertebral osteomyelitis 7 (15.6) 16 (26.2) .091
 Infected osteosynthesis 3 (6.7) 11 (18.0) .089
 Arthritis 12 (26.7) 11 (18.0) .291
 Prosthetic joint infection 5 (11.1) 7 (11.5) .954
 Splenic abscess 0 2 (3.3) .224
 Soft tissue abscess 25 (55.6) 33 (54.1) .883
 Pulmonary foci 17 (37.8) 12 (19.7) .039
Total, n 83 101  
Relapse 0 0  
3-Month mortality, n (%) 6 (13.3) 4 (6.6) .242
Drainage, radiologically or surgically, n (%) 26 (57.8) 31 (50.1) .666
Hospital admission duration, median (IQR), days 29 (33) 17 (11) .001
Treatment duration, median (IQR), days 45 (44) 45 (49) .355
Addition of rifampicin, n (%) 15 (33.3) 16 (26.2) .643
Adverse events,a n (%) 25 (55.6) 30 (49.2) .516
 Phlebitis 16 (35.6) 24 (39.3) .691
 Central venous line–related infection 0 1 (1.6) 1.000
 Central venous line–related thrombosis 0 0  
 Rash 1 (2.2) 1 (1.6) 1.000
 Acute kidney injury 6 (13.3) 2 (3.3) .069
 Nausea/vomiting 1 (2.2) 2 (3.3) 1.000
 Clostridiodes difficile infection 2 (4.4) 0  
 Increased liver enzymes 3 (6.7) 0  
Abbreviations: IQR, interquartile range; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus.
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Twenty-five adverse events were observed in the prolonged IV 
treatment group: 17 (68.0%) within 2 weeks and 8 (32.0%) after 
2 weeks of treatment. Of these 8 late adverse events, 4 were phle-
bitis and 4 were AKI. In the IV-oral switch group, all 30 adverse 
events were reported in the first 2 weeks of IV antibiotic treatment. 
In all patients, phlebitis occurred only in patients who received 
flucloxacillin via a peripheral IV catheter. Acute kidney injury was 
only reported in patients who were on IV flucloxacillin and oc-
curred more often in the prolonged IV group (13.3% vs 3.3% in the 
IV-oral switch group; P = .069). Other adverse events are shown 
in Table 1.
DISCUSSION
This retrospective single-center study showed that IV-oral 
switch after 14  days of IV treatment was not associated with 
relapses in a selected group of patients with complicated SAB 
without signs of endovascular infection on echocardiography 
and 18F-FDG-PET/CT. The 3-month mortality rate was low in 
both groups and not statistically different. Importantly, almost 
60% of the patients were considered clinically eligible for IV-oral 
switch. Reasons for continuation of IV antibiotic treatment in 
the other patients were unknown, but patient characteristics 
showed that patients with prolonged IV antibiotic treatment 
included significantly more high-risk populations (Table 1). 
Moreover, IV-oral switch was associated with a shorter length 
of hospital stay and no adverse events were reported during oral 
antibiotic treatment.
To ensure sterilization of the metastatic foci, international 
guidelines recommend prolonged IV antibiotic treatment for at 
least 4–6 weeks in patients with complicated SAB [1, 6]. The 
present study, however, showed that eradication of deep-seated 
nonendovascular infectious foci complicating SAB is also pos-
sible with oral stepdown. The majority of patients with IV-oral 
switch were treated with clindamycin. The high bioavailability 
and excellent bone and abscess penetration of clindamycin 
make it well suited as an oral alternative for the treatment of 
S. aureus infections. Based on in vitro data, clindamycin is clas-
sified as a bacteriostatic agent, causing hesitation to use this an-
tibiotic for serious infections. However, the in vitro distinction 
between bacteriostatic and bactericidal does not translate well 
to clinical situations. This also applies to gram-positive infec-
tions [7] and our study shows that an excellent outcome with a 
bacteriostatic agent can be obtained in a selected group of pa-
tients. There are several studies demonstrating the efficacy of 
oral stepdown therapy for SAB with other highly bioavailable 
oral antibiotics such as linezolid or fluoroquinolones with ri-
fampicin [2, 3], which suggests that clindamycin may also be a 
sound choice, as shown in this study.
No relapses were reported in either group of patients. This 
contrasts with reported relapse rates of 2–23% [6]. One ex-
planation for our low relapse rate is the extensive diagnostic 
workup we performed in patients with SAB, including echocar-
diography and 18F-FDG-PET/CT in case of the presence of risk 
factors for complicated SAB [5]. Performance of 18F-FDG-PET/
CT in patients with SAB is associated with lower mortality and 
relapse rates [5].
IV-oral switch is one of the goals that antimicrobial stew-
ardship teams focus on, because it reduces costs and length 
of hospital stay [8]. Correspondingly, in the present study, the 
median duration of hospital admission was 12  days shorter 
in patients with IV-oral switch compared with patients with 
prolonged IV antibiotic treatment. Phlebitis was frequently 
reported and was probably related to the physicochemical 
properties of flucloxacillin [9], because it was not observed 
during treatment with cefazolin. All patients with AKI were 
treated with flucloxacillin. The etiology of AKI in these pa-
tients was probably tubule-interstitial nephritis, as shown in 
other studies that reported higher rates of nephrotoxicity in 
patients receiving anti-staphylococcal penicillin compared 
with cefazolin [10].
A limitation of our study is its retrospective design with a rel-
atively small population sample. Inherent to the retrospective 
noninterventional design of our study is the risk of bias due to 
confounding by indication.
Our results provide evidence to the efficacy and safety of 
IV-oral switch in a specific group of patients with compli-
cated SAB (96.2% methicillin-susceptible S. aureus [MSSA]) ie, 
without endovascular infection and complex deep-seated infec-
tions, such as undrained epidural abscesses. An individualized 
approach in a multidisciplinary setting to define treatment of 
complicated SAB could lead to a safe IV-oral switch with a re-
duction in adverse events and length of hospital stay in these 
patients. Prospective studies should further validate IV-oral 
switch for the treatment of complicated MSSA bacteremia.
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